Navigation Links
Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
Date:9/30/2013

HOUSTON, Sept. 30, 2013 /PRNewswire/ -- Moleculin, LLC, a clinical-stage pharmaceutical company focused on developing topical treatments for inflammatory and proliferative skin diseases, today announced positive results from a double-blind, randomized Phase 2a study with MOL4249, a novel compound in development for the treatment of psoriasis. In the study, MOL4249 was shown to be effective in the treatment of mild-to-moderate plaque psoriasis when compared to the vehicle, with no detectable side effects.

"Despite the many treatment options available today, psoriasis continues to be an underserved skin disease with need for improvements in both efficacy and long-term tolerability over available therapies," said Walter Klemp, Chairman and CEO of Moleculin. "The Phase 2 data for MOL4249 are very encouraging and support our plans for continued study in larger numbers of patients."

Study Details

The double-blind, controlled, Phase 2a study involved 16 patients with mild-to-moderate plaque psoriasis. Of these, 10 patients were treated with a topical compound containing MOL4249, while 6 were treated with a control vehicle. Patients applied the treatment twice a day for 28 consecutive days. 50% of patients treated with MOL4249 showed a 50% or better improvement in lesions, versus 17% for the vehicle. In addition, 30% of MOL4249 patients demonstrated a 75% or better improvement in lesions, versus 17% for the vehicle.

Patients and physicians reported no adverse events in the study, suggesting the potential of a topical treatment for psoriasis that is safe for long-term use. MOL4249 is a first-in-class small molecule drug that works by directly inhibiting p-STAT3, a novel target that may contribute to many chronic skin diseases regardless of its activating pathway. Data suggest that this unique mechanism of action may significantly reduce the incidence of side effects, making this compound safe for long-term, chronic use.

About Psoriasis

Psoriasis is a chronic autoimmune skin disease that occurs when the immune system mistakenly speeds up the growth cycle of skin cells. It affects up to 7.5 million Americans and can be difficult to treat because of side effects such as atrophy, or thinning of the skin, with long-term use.

Plaque psoriasis is the most common form of the disease in which people develop itchy skin spots, red patches, and a silvery white buildup of dead skin cells most often appearing on the scalp, lower back, knees, and elbows.

According to a patient survey conducted in the U.S. between 2001 and 2008 by the National Psoriasis Foundation, 33% of patients with mild disease and 60% of patients with moderate-to-severe psoriasis reported that their disease significantly affects their everyday life.

About Moleculin

Moleculin is a clinical-stage pharmaceutical company advancing a new therapeutic approach to inflammatory and proliferative skin diseases, including psoriasis, atopic dermatitis, actinic keratosis, and several skin cancers. The Company's topical compounds are based on the direct inhibition of activated STAT3 (p-STAT3), an important target in the fight against chronic skin diseases. MOL4249, the Company's lead product candidate, is currently being studied in psoriasis. Early clinical studies with this p-STAT3 inhibitor suggest improved efficacy and tolerability for the treatment of mild-to-moderate psoriasis. For more information, visit moleculin.com.


'/>"/>
SOURCE Moleculin, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
2. Allied Healthcare Products Reports Loss On Sales Decline
3. TPI Reports Fiscal Year 2013 Financial Results
4. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
5. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
6. Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy
7. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
8. Apollo Medical Holdings Reports Record Fiscal 2014 Second Quarter Results
9. Cyberonics Reports Inducement Equity Award Under NASDAQ Listing Rule 5635(c)(4)
10. Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
11. Omeros Reports Additional Positive Results from OMS824 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016 Intec Pharma Ltd. ... biopharmaceutical company, today announced the appointment of Pnina ... "Ms. Strauss-Levy has 15 years of experience ... an outstanding track record, having supported the advancement of ... processes in the United States ...
(Date:5/3/2016)... May 3, 2016 Global ... provides a basic overview of the industry that ... the surgical mesh report explores into the international ... Complete report on Surgical Mesh market spread across ... tables and figures is available at http://www.reportsnreports.com/reports/470569-global-and-chinese-surgical-mesh-industry-2016-market-research-report.html ...
(Date:5/2/2016)... 2016 Kalorama Information noted the 5 Most ... in a recent white paper.  The healthcare market research ... a growing market are among the top drivers of ... EMR 2016: The Market for Electronic Medical ... study of the EMR industry, and the report is ...
Breaking Medicine Technology:
(Date:5/4/2016)... , ... May 04, 2016 , ... ... of patented products, announces the Everlasting Glove, a sports invention that aids in ... and Sporting Goods Manufacturing industry is worth $9 billion," says Scott Cooper, CEO ...
(Date:5/4/2016)... ... May 04, 2016 , ... Connor Sport Court International’s ... the 2016 NCAA Men’s National Collegiate Volleyball Championship. , Sport Court’s ... to be held May 5-7 at Pennsylvania State University’s Rec Hall in University ...
(Date:5/4/2016)... NY (PRWEB) , ... May 04, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – is set to return to the esteemed Quaker Ridge Golf Club in ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nike Rugby Camp's success is due in ... Willis, founder of Elite Rugby Camps and current Nike Camp director, has offered an ... 2009. , “I’m excited for our eighth summer here in San Diego,” says ...
(Date:5/4/2016)... ... May 04, 2016 , ... Washington Wellness Center today announced its ... Jersey residents. What started out as an idea to provide a holistic approach ... to healthcare. , Developed by Dr. David Swanekamp, Chiropractic Physician , the wellness ...
Breaking Medicine News(10 mins):